 | • レポートコード：MRC2302F0236 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、255ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、2021年の8,092.56百万ドルであった世界の急性冠症候群（ACS）治療薬市場規模が、2022年に8,657.44百万ドルへ達し、2027年までに年平均7.15%成長し、12,252.27百万ドルへ拡大すると見込んでいます。本書は、急性冠症候群（ACS）治療薬の世界市場を対象に、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、種類別（非ST上昇型心筋梗塞、ST上昇型心筋梗塞、バイアル型不安定狭心症）分析、薬剤別（降圧剤、抗血栓薬、スタチン）分析、治療別（薬物治療、退院後治療、入院前治療、再灌流療法）分析、診断別（血液検査、コンピュータ断層撮影（CT）血管造影、冠動脈造影検査、心エコー図、画像診断）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目について調査・分析を行っています。また、市場調査の対象企業には、AbbVie Inc.、Amgen Inc.、Arena Pharmaceuticals, Inc.、AstraZeneca PLC、Baxter International Inc.、Bayer AG、Biogen Inc.などが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の急性冠症候群（ACS）治療薬市場規模：種類別 - 非ST上昇型心筋梗塞の市場規模 - ST上昇型心筋梗塞の市場規模 - バイアル型不安定狭心症の市場規模 ・世界の急性冠症候群（ACS）治療薬市場規模：薬剤別 - 降圧剤における市場規模 - 抗血栓薬における市場規模 - スタチンにおける市場規模 ・世界の急性冠症候群（ACS）治療薬市場規模：治療別 - 薬物治療における市場規模 - 退院後治療における市場規模 - 入院前治療における市場規模 - 再灌流療法における市場規模 ・世界の急性冠症候群（ACS）治療薬市場規模：診断別 - 血液検査における市場規模 - コンピュータ断層撮影（CT）血管造影における市場規模 - 冠動脈造影検査における市場規模 - 心エコー図における市場規模 - 画像診断における市場規模 ・世界の急性冠症候群（ACS）治療薬市場規模：地域別 - 南北アメリカの急性冠症候群（ACS）治療薬市場規模 アメリカの急性冠症候群（ACS）治療薬市場規模 カナダの急性冠症候群（ACS）治療薬市場規模 ブラジルの急性冠症候群（ACS）治療薬市場規模 ... - アジア太平洋の急性冠症候群（ACS）治療薬市場規模 日本の急性冠症候群（ACS）治療薬市場規模 中国の急性冠症候群（ACS）治療薬市場規模 インドの急性冠症候群（ACS）治療薬市場規模 韓国の急性冠症候群（ACS）治療薬市場規模 台湾の急性冠症候群（ACS）治療薬市場規模 ... - ヨーロッパ/中東/アフリカの急性冠症候群（ACS）治療薬市場規模 イギリスの急性冠症候群（ACS）治療薬市場規模 ドイツの急性冠症候群（ACS）治療薬市場規模 フランスの急性冠症候群（ACS）治療薬市場規模 ロシアの急性冠症候群（ACS）治療薬市場規模 ... - その他地域の急性冠症候群（ACS）治療薬市場規模 ・競争状況 ・企業情報 |
The Global Acute Coronary Syndrome Therapeutics Market size was estimated at USD 8,092.56 million in 2021 and expected to reach USD 8,657.44 million in 2022, and is projected to grow at a CAGR 7.15% to reach USD 12,252.27 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Acute Coronary Syndrome Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Type, the market was studied across Non-ST-elevation Myocardial Infarction, ST-elevation Myocardial Infarction, and Vial Unstable Angina.
Based on Drug, the market was studied across Antihypertensive, Antithrombotic, and Statins.
Based on Treatment, the market was studied across Drug Treatment, Post Discharge Treatment, Prehospital Care, and Reperfusion Therapy. The Drug Treatment is further studied across Antianginal Drug, Anticoagulant, and Antiplatelet Drug.
Based on Diagnosis, the market was studied across Blood Tests, Computerized Tomography Angiogram, Coronary Angiogram, Echocardiogram, and Imaging.
Based on End User, the market was studied across Academic Institutes, Diagnostic Centers, and Hospital & Clinics.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Acute Coronary Syndrome Therapeutics market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Acute Coronary Syndrome Therapeutics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Acute Coronary Syndrome Therapeutics Market, including AbbVie Inc., Amgen Inc., Arena Pharmaceuticals, Inc., AstraZeneca PLC, Baxter International Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and XOMA Corporation.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Acute Coronary Syndrome Therapeutics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Acute Coronary Syndrome Therapeutics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Acute Coronary Syndrome Therapeutics Market?
4. What is the competitive strategic window for opportunities in the Global Acute Coronary Syndrome Therapeutics Market?
5. What are the technology trends and regulatory frameworks in the Global Acute Coronary Syndrome Therapeutics Market?
6. What is the market share of the leading vendors in the Global Acute Coronary Syndrome Therapeutics Market?
7. What modes and strategic moves are considered suitable for entering the Global Acute Coronary Syndrome Therapeutics Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increased cases of atherosclerosis (myocardial infarction) and unstable angina
5.1.1.2. Growing aging population and poor immune systems
5.1.1.3. Increased pharmaceutical R&D investment and introduction of innovative drugs
5.1.2. Restraints
5.1.2.1. Obstruction due to less number of approved drugs for the treatment of acute coronary syndrome
5.1.3. Opportunities
5.1.3.1. Reperfusion of the myocardium and prevent reinfarction in order to promote patient survival
5.1.3.2. Extensive pipeline drugs with properties, such as high patient compliance and improved safety
5.1.3.3. Improving health care infrastructure and government reimbursement programs
5.1.4. Challenges
5.1.4.1. Cost and formulation
5.2. Cumulative Impact of COVID-19
6. Acute Coronary Syndrome Therapeutics Market, by Type
6.1. Introduction
6.2. Non-ST-elevation Myocardial Infarction
6.3. ST-elevation Myocardial Infarction
6.4. Vial Unstable Angina
7. Acute Coronary Syndrome Therapeutics Market, by Drug
7.1. Introduction
7.2. Antihypertensive
7.3. Antithrombotic
7.4. Statins
8. Acute Coronary Syndrome Therapeutics Market, by Treatment
8.1. Introduction
8.2. Drug Treatment
8.3.1. Antianginal Drug
8.3.2. Anticoagulant
8.3.3. Antiplatelet Drug
8.3. Post Discharge Treatment
8.4. Prehospital Care
8.5. Reperfusion Therapy
9. Acute Coronary Syndrome Therapeutics Market, by Diagnosis
9.1. Introduction
9.2. Blood Tests
9.3. Computerized Tomography Angiogram
9.4. Coronary Angiogram
9.5. Echocardiogram
9.6. Imaging
10. Acute Coronary Syndrome Therapeutics Market, by End User
10.1. Introduction
10.2. Academic Institutes
10.3. Diagnostic Centers
10.4. Hospital & Clinics
11. Americas Acute Coronary Syndrome Therapeutics Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Acute Coronary Syndrome Therapeutics Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Acute Coronary Syndrome Therapeutics Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.1.1. Quadrants
14.1.2. Business Strategy
14.1.3. Product Satisfaction
14.2. Market Ranking Analysis, By Key Player
14.3. Market Share Analysis, By Key Player
14.4. Competitive Scenario
14.4.1. Merger & Acquisition
14.4.2. Agreement, Collaboration, & Partnership
14.4.3. New Product Launch & Enhancement
14.4.4. Investment & Funding
14.4.5. Award, Recognition, & Expansion
15. Company Usability Profiles
15.1. AbbVie Inc.
15.1.1. Business Overview
15.1.2. Key Executives
15.1.3. Product & Services
15.2. Amgen Inc.
15.2.1. Business Overview
15.2.2. Key Executives
15.2.3. Product & Services
15.3. Arena Pharmaceuticals, Inc.
15.3.1. Business Overview
15.3.2. Key Executives
15.3.3. Product & Services
15.4. AstraZeneca PLC
15.4.1. Business Overview
15.4.2. Key Executives
15.4.3. Product & Services
15.5. Baxter International Inc.
15.5.1. Business Overview
15.5.2. Key Executives
15.5.3. Product & Services
15.6. Bayer AG
15.6.1. Business Overview
15.6.2. Key Executives
15.6.3. Product & Services
15.7. Biogen Inc.
15.7.1. Business Overview
15.7.2. Key Executives
15.7.3. Product & Services
15.8. Boehringer Ingelheim International GmbH
15.8.1. Business Overview
15.8.2. Key Executives
15.8.3. Product & Services
15.9. Eli Lilly and Company
15.9.1. Business Overview
15.9.2. Key Executives
15.9.3. Product & Services
15.10. Gilead Sciences, Inc.
15.10.1. Business Overview
15.10.2. Key Executives
15.10.3. Product & Services
15.11. GlaxoSmithKline PLC
15.11.1. Business Overview
15.11.2. Key Executives
15.11.3. Product & Services
15.12. Johnson & Johnson Services, Inc.
15.12.1. Business Overview
15.12.2. Key Executives
15.12.3. Product & Services
15.13. Merck & Co., Inc.
15.13.1. Business Overview
15.13.2. Key Executives
15.13.3. Product & Services
15.14. Novartis International AG
15.14.1. Business Overview
15.14.2. Key Executives
15.14.3. Product & Services
15.15. Pfizer Inc.
15.15.1. Business Overview
15.15.2. Key Executives
15.15.3. Product & Services
15.16. Teva Pharmaceutical Industries Ltd.
15.16.1. Business Overview
15.16.2. Key Executives
15.16.3. Product & Services
15.17. XOMA Corporation
15.17.1. Business Overview
15.17.2. Key Executives
15.17.3. Product & Services
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing